Anti-RNPC3 autoantibodies were associated with a higher frequency of SSc skin involvement in patients with MCTD. Anti-RNPC3 autoantibodies, especially in high titers, might be the markers for an increased risk of cancer in MCTD that needs to be confirmed in larger cohorts.
Jalaledin et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: